Shares of SAB Biotherapeutics are up 33% or 25c per share to $1.02 in late afternoon trading on Tuesday after the immunotherapies biopharma announced that the U.S. Food and Drug Administration, FDA, had granted Breakthrough Therapy Designation, BTD, to SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SABS:
- SAB Biotherapeutics Blasts Up on Flu Treatments
- SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
- SAB Biotherapeutics announces U.S. FDA grants BTD to SAB-176
- SAB Biotherapeutics granted Fast Track designation from FDA for SAB-176
- SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
